Eine Studie mit 21 Kindern bzw. Jugendlichen mit chronischen täglichen Kopfschmerzen (CDH) im Alter von 6 - 18 Jahren konnte z. T. deutliche Symptomverbesserungen bei einer niedrigdosierten Topamax-Anwendung von 30mg (Topiramat) beobachten.
62% der Familien berichteten eine signifikante Verbesserung bei den Kopfschmerzen. Die Kopfschmerzfrequenz reduzierte sich auf 7,2 von 22,8 pro Monat und die Kopfschmerzstärke nahm von 8,1 auf 3,7 ab.
Abstract:
Effectiveness of Topiramate in the Treatment of Pediatric Chronic Daily Headache
Borzy JC, Koch TK, Schimschock JR.
Department of Pediatrics, Division of Pediatric Neurology, Doernbecher Children's Hospital, Oregon Health and Science University, Portland, Oregon.
This study reports on the efficacy and safety of low-dose topiramate in the treatment of pediatric patients with chronic daily headache. Topiramate is one of the new antiepileptic drugs commonly being used for migraine prophylaxis in adults as well as children and was recently approved by the Food and Drug Administration for migraine treatment in adults. This report presents our experience with low-dose topiramate for the treatment of chronic daily headache using a retrospective parental survey of 21 patients ranging in age from 6 to 18 years. Efficacy and safety were evaluated using a parental assessment and satisfaction questionnaire. Sixty-two percent of families reported that low-dose topiramate (average dose of 30 mg/day) was successful in reducing both the frequency and severity of headache episodes. The headache frequency decreased from 22.8 headaches/month to 7.2 headaches/month and severity decreased from a pain score of 8.1 to 3.7. Topiramate was safe, well tolerated, and highly effective at low doses in the treatment of chronic daily headaches.
Weitere Infos finden sich hier.
